NikeBio is a leading biotechnology company that specializes in the manufacturing and sale of life science research products and services. Our paramount mission is to become your ultimate trusted and reliable partner in gene therapy research and development. We excel in providing efficient and robust production of nucleic acid materials, high-throughput viral vector production, and comprehensive analytical characterization. With our unwavering commitment, our services accompany you seamlessly throughout the entire research and development process, encompassing the entire streamlined journey. We cater specifically to early-stage drug discovery, preclinical development, and clinical trials for Cell and Gene Therapy (CGT).

At NikeBio, we are at the forefront of innovative, developing a state-of-the-art virus production platform based on our proprietary cceAAV (Covalently closed ends AAV) technology. This groundbreaking technology not only enhances potency but also addresses safety concerns and significantly reduces manufacturing timelines. Our team of experts possesses extensive knowledge and experience in delivering AAV therapeutic solutions using our innovative technology, thereby supporting the manufacturing of AAV-based therapies.

To ensure the highest quality standards, we employ a meticulous Quality by Design approach in our process development. Through triple transfection of suspension HEK293 systems, we define a set of critical process parameters for AAV manufacturing. With our well-established AAV manufacturing process, we can produce a substantial 1.0E16 VG AAV vector drug substance at 50L scales, catering to a wide range of requirements spanning from R&D to clinical development phases.